BioSpace News Archive

Rising incidence of immunodeficiency diseases and increase in geriatric population are key factors driving market revenue growth.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,501,239 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 9,748,761 shares of its common stock at an exercise price of $0.01 per share.

GENFIT announced the filing of its 2021 Universal Registration Document with the Autorité des marchés financiers and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission, as well as the availability of preparatory documents for its annual shareholders meeting on Wednesday May 25, 2022.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 12:00 p.m. Pacific Time.

PTC Therapeutics, Inc. announced that management will present a company overview at the following conferences.

Eiger BioPharmaceuticals, Inc. reported that the Compensation Committee of Eiger’s Board of Directors granted stock options to purchase an aggregate of 290,000 shares of Eiger’s common stock to two newly hired employees.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), announced today that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older.

Procaps Group S.A., a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced its financial results for the fourth quarter and fiscal year ended December 31, 2021.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its first-quarter 2022 financial results on May 11 at 8.30 a.m. EDT.

Grifols, S.A. announced that it has filed its 2021 Annual Report on Form 20-F with the United States Securities and Exchange Commission on April 29, 2022.